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Abstract
Epithelial-to-mesenchymal transition (EMT) facilitates the escape of epithelial cancer cells from the primary tumor
site, which is a key event early in metastasis. Here, we explore how extrinsic, tumor microenvironmental cytokines
cooperate with intrinsic, genetic changes to promote EMT in human mammary epithelial cells (HMECs). Viral trans-
duction of transforming genetic events into HMECs routinely generated two distinct cell populations. One popu-
lation retained epithelial characteristics, while an emergent population spontaneously acquired a mesenchymal
morphology and properties associated with cancer stem cells (CSCs). Interestingly, the spontaneous mesenchymal/
CSCs were unable to differentiate and lacked epithelial-mesenchymal plasticity. In contrast, exposure of the trans-
formed HMECs retaining epithelial characteristics to exogenous transforming growth factor–β (TGF-β) generated a
mesenchymal/CSC population with remarkable plasticity. The TGF-β–induced mesenchymal/CSC population was
dependent on the continued presence of TGF-β. Removal of TGF-β or pharmacologic or genetic inhibition of TGF-β/
SMAD signaling led to the reversion of mesenchymal/CSC to epithelial/non-CSC. Our results demonstrate that target-
ing exogenous cytokine signaling disrupts epithelial-mesenchymal plasticity andmay be an effective strategy to inhibit
the emergence of circulating tumor cells. The model of epithelial-mesenchymal plasticity we describe here can be
used to identify novel tumor microenvironmental factors and downstream signaling that cooperate with intrinsic
genetic changes to drive metastasis. Understanding the interaction between extrinsic and intrinsic factors that regulate
epithelial-mesenchymal plasticity will allow the development of new therapies that target tumor microenvironmental
signals to reduce metastasis.
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Introduction
Metastasis is the cause of breast cancer fatality [1]. Metastasis consists
of four steps, namely, invasion and entry of primary tumor cells into
the circulatory system, survival of circulating tumor cells (CTCs),
movement from the circulation into a secondary tissue, and tumor
growth at a secondary site [2]. The changes that occur in cancer cells
that allow them to accomplish these steps and metastasize remain
poorly understood.
Epithelial-to-mesenchymal transition (EMT) occurs during normal
organism development, wound healing, and formation of branched
tissue, such as lung or breast [3–6]. In normal breast tissue, tight
cell-cell interactions anchor epithelial cells to each other creating a
physical hindrance to cell dispersal and a natural barrier to metastasis
[7,8]. It has been proposed that epithelial tumor cells undergo EMT,
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releasing mesenchymal-like cells that are motile and invasive and
can initiate metastasis [9,10]. While EMT allows release of tumor
cells from primary cancer sites, evidence supports that a reciprocal
mesnchymal-to-epithelial transition occurs at distant sites [11]. Thus,
metastasis requires that a tumor cell gain the capacity to transition
between epithelial and mesenchymal states. Epithelial-mesenchymal
plasticity would allow epithelial tumor cells in the primary tumor
to acquire invasive and survival programs associated with a mesen-
chymal state, escape from the primary tumor, survive as a CTC,
and then revert to an epithelial state at secondary sites.
The regulation of epithelial-mesenchymal plasticity is likely to be
dependent on non-tumor cells in the tumor microenvironment,
which include a variety of tumor-associated stromal cells, such as fibro-
blasts, infiltrating immune cells, and endothelial cells [12]. As a tumor
develops, changes occur not only in the epithelial tumor cells but also in
nearby tumor-associated stromal cells. Indeed, analysis of breast tumor
stroma identified elevated levels of a variety of growth factors, cyto-
kines, and chemokines compared to normal breast stroma [13]. How-
ever, it remains unclear how each of these tumor-associated factors
influences tumor cell growth and epithelial-mesenchymal plasticity.
Seminal work demonstrated that EMT of transformed human
mammary epithelial cells (HMECs) generates mesenchymal-like cells
with properties associated with breast cancer stem cells (CSCs) [14].
Breast CSCs are identified by a CD24−/CD44+ cell surface marker
profile [15]. When sorted from breast cancer tumors, CD24−/CD44+
cells generate a variety of differentiated progeny and form tumors that
recapitulate the histology of the patients’ primary tumors [15]. In con-
trast, CD24+/CD44− cells are unable to efficiently form tumors and
are referred to as non-CSCs. The ability of epithelial/non-CSC to
undergo EMT and acquire CSC properties is now believed to play a
role in therapeutic resistance and metastasis.
The current study demonstrates that exogenous cytokine signaling
from the tumor microenvironment can cooperate with defined,
intrinsic genetic changes to generate tumor cell plasticity. Exogenous
cytokine exposure converted epithelial/non-CSC to mesenchymal/
CSC through activation of EMT. Interestingly, maintenance of
mesenchymal/CSC required continuous exposure to cytokine, as
removal caused reversion to an epithelial/non-CSC population.
Generation and maintenance of mesenchymal/CSC could be blocked
by disrupting components of endogenous cytokine signaling. The
results presented here suggest that targeting epithelial-mesenchymal
plasticity may be an effective strategy to reduce tumor formation,
progression, and metastasis leading to improved patient outcomes.
As such, epithelial-mesenchymal plasticity can be disrupted by target-
ing the epithelial tumor cells as described here or inhibiting the
generation of soluble factors by the tumor-associated stromal cells.
Materials and Methods
Cell Growth
HMECs were obtained from discarded surgical material under
Institutional Review Board (IRB) approval. Specimen 48R, specimen
J (SJ), and derivatives were grown as described previously [16,17]. Treat-
ments were 10 ng/ml human recombinant transforming growth fac-
tor–β1 (TGF-β1, 100-21; PeproTech Inc, Rocky Hill, NJ), 5 μM
phosphoinositide 3-kinase (PI3K) inhibitor LY294002 (LY, 70920;
Cayman Chemical, Ann Arbor, MI), 100 mM mammalian target
of rapamycin (mTOR) inhibitor rapamycin (RAP, 553210; EMD
Millipore, Billerica, MA), and 20 μMTGF-β receptor type I (TGFβRI)
inhibitor SB431542 (SB; S4317; Sigma-Aldrich, St Louis, MO). Soft
agar assays were described previously [16,18].
Viral Infections
48R HMECs were transduced as previously described [16]. SJ
HMECs were transduced similarly, except pRetroSUPER-shp53-
puro was used [19]. Kinase dead dominant negative TGF-β–activated
kinase 1 (DN–TAK-1) cDNA, dominant negative TGF-β receptor
type II (DN-TGFβRII), and SMAD7 were cloned into pLPCX
(631511; Clontech, Mountain View, CA) [20–22].
Microscopy
Bright-field images were captured at ×4 on a Nikon Eclipse
TE2000-S using MetaMorph (Molecular Devices, Sunnyvale, CA).
For confocal analyses, 1.5 × 105 cells were plated onto 35-mm glass
bottom microwell dishes (P35G-1.5-20-C; MatTek Corp, Ashland,
MA) for growth overnight. Cells were fixed and permeabilized
in 100% methanol and stained overnight with 1:50 dilutions of
E-cadherin (clone 67A4, SC-21791-AF647) and vimentin (clone V9,
SC-6260-AF488; Santa Cruz Biotechnology, Santa Cruz, CA). Nuclei
were counterstained with 50 μg/ml Hoechst dye. Images were captured
by oil immersion at ×100 on a Zeiss LSM 510 using AIM software.
Flow Cytometry
Cells (2 × 106) were stained with 20 μl of epithelial cell adhesion
molecule (EpCAM)–fluorescein isothiocyanate (clone VU-1D9;
STEMCELL Technologies, Vancouver, BC) or 20 μl each of CD24-
phycoerythrin (PE) (clone ALB9, IM1428U; Beckman Coulter, Brea,
CA) and CD44-allophycocyanin (APC) (clone C26, 559942; BD
Biosciences, San Jose, CA) for analysis on LSRII using FACSDiva
version 6.2 software (Becton Dickinson, San Jose, CA).
Western Blot Analysis
Western blots were conducted as described previously [16]. Anti-
bodies used were E-cadherin (clone 67A4, SC-21791), vimentin (clone
V9, SC-6260; Santa Cruz Biotechnology), and actin (ACTN05,
MS-1295; Thermo Scientific, Waltham, MA).
Quantitative Real-Time Reverse Transcription–Polymerase
Chain Reaction
Total ribonucleic acid (RNA) was isolated using an RNeasy Mini
Kit (Qiagen, Valencia, CA) with on-column DNase I digest. RNA
(1 μg) was reverse transcribed by RT2 First Strand Kit (C-03/330401).
The RT2 Profiler PCR Array System (SABiosciences, Frederick, MD)
for EMT (PAHS-090D) and TGF-β/bone morphogenetic protein
(BMP) signaling pathway (PAHS-035D) was analyzed on a CFX96
thermocycler (Bio-Rad, Hercules, CA).
Phospho-Kinase Arrays
A Proteome Profiler Human Phospho-Kinase Array Kit (ARY003;
R&D Systems, Minneapolis, MN) was used according to the manu-
facturer’s instructions.
Mouse Xenografts
Animal studies were approved by the Case Western Institutional
Animal Care and Use Committee. Cells (1 × 106) were flank injected
with 50% growth factor–reduced Matrigel (353261; BD Biosciences)
in NCR nu/nu mice irradiated 4 hours previously with 400 rad.
Tumors were resected at 12 weeks, fixed with formalin, paraffin
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embedded, sliced, mounted to slides, and stained with hematoxylin
and eosin. Images were captured at ×400 on an Olympus BX45 with
a SPOT Idea camera (software version 5). One tumor was dissociated
overnight using collagenase (C0130) and hyaluronidase (H3506;
Sigma-Aldrich). Infiltrating mouse cells were eliminated by selection
with 200 μg/ml G418.
Results
Transformation of HMECs Generates a Subset of
Mesenchymal-Like Cells through EMT
Starting with normal HMECs from elective breast reduction
mammoplasty, we have developed a genetically defined, stepwise
protocol to achieve consistent transformation. Specimen 48R
HMECs were infected with viruses encoding short hairpin RNA
(shRNA) targeting p16 then p53 (48R-shp16-shp53). 48R-shp16-
shp53 populations were subsequently infected with retroviruses
encoding RAS alone, MYC alone, MYC and RAS together (M/R),
or a vector control retrovirus. Each of the derivatives was plated in soft
agar (200,000 cells/plate) to assess anchorage-independent growth
(AIG). Robust AIG of 48R HMECs was only observed when all four
genetic events were combined together (Figure 1A). Interestingly, a
population of cells with a spindle-shaped morphology, indicative of
mesenchymal-like cells, emerged within the 48R-shp16-shp53–M/R
cells (48-Mixed; Figure 1B, top panel ). The cells with mesenchymal-
like morphology (48-Mesenchymal) were weakly attached to the sub-
stratum and could be separated from the epithelial cells (48-Epithelial)
by differential trypsinization (Figure 1B, bottom panels).
Flow cytometry was used to determine the expression of the epi-
thelial cell surface marker EpCAM in each of the isolated populations.
Figure 1. HMEC transformation generates a subset of mesenchymal-like cells through EMT. 48-shp16-shp53 HMECs were further
infected with control retrovirus (Vec) or retroviruses encoding MYC alone (MYC), RAS alone (RAS), or MYC and RAS together (M/R).
(A) Quantification of AIG. (B) Bright-field microscopy (×4) of 48R-shp16-shp53–M/R cells (48-Mixed) revealed cells with mesenchymal-
like morphology (arrowheads). The mesenchymal-like cells (48-Mesenchymal) could be separated from the epithelial cells (48-Epithelial)
by differential trypsinization. Characterization of the 48-Mixed, 48-Epithelial, and 48-Mesenchymal cells by (C) analysis of EpCAM,
(D) Western blot, (E) confocal microscopy (×100) for E-cadherin (red), vimentin (green), and nuclei (blue), (F) EMT-related gene expression
changes, and (G) phospho-protein differences.
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The 48-Epithelial population was 86.1% positive for EpCAM, while
only 3.4% of the 48-Mesenchymal population expressed EpCAM
(Figure 1C ). Thus, the 48-Mixed cells consisted of two isogenic cell
populations with epithelial-like and mesenchymal-like morphologies
that could be isolated from one another with greater than 85% purity
by differential trypsinization.
Because the 48-Mixed cells consisted of both epithelial- and
mesenchymal-like cellular morphologies, we hypothesized that a spon-
taneous EMT had occurred during transformation to generate the
48-Mesenchymal population. To test this hypothesis, the 48-Mixed,
48-Epithelial, and 48-Mesenchymal populations were characterized
for known markers of EMT. Western blot and confocal analyses
demonstrated that the epithelial marker E-cadherin is expressed in
the 48-Epithelial cells, while the mesenchymal marker vimentin is ex-
pressed in the 48-Mesenchymal cells with mutual exclusivity (Figure 1,
D and E ). The 48-Epithelial and 48-Mesenchymal cells were sub-
jected to a targeted EMT quantitative real-time reverse transcription–
polymerase chain reaction (qRT-PCR) array, which confirmed the loss
of E-cadherin gene transcription in the 48-Mesenchymal population
as well as decreased expression of genes whose loss is associated with
EMT, such as caveolin 2, occludin, desmocollin 2, and keratin 19 among
others (Figure 1F ). In addition, qRT-PCR confirmed increased gene
transcription of vimentin in the 48-Mesenchymal population as well
as increased gene expression of snail, twist, zeb1, and zeb2, among
others, all known arbiters of EMT (Figure 1F ).
Previous studies have demonstrated that EMT of transformed
HMECs requires canonical and non-canonical WNT signaling [23].
The EMT expression array confirmed increases in components of
WNT signaling (WNT5a, TCF4, and FZD7) in the 48-Mesenchymal
population compared to the expression levels in the 48-Epithelial pop-
ulation (Figure 1F ). In addition to the targeted EMT expression array,
the 48-Epithelial and 48-Mesenchymal populations were subjected to
analysis of protein phosphorylation using a targeted phospho-kinase
antibody array. Increased AKT phosphorylation at serine 473 was evi-
dent in the 48-Mesenchymal population, indicating that mTOR
signaling is activated (Figure 1G ). Additionally, β-catenin total phos-
phorylation was diminished in the 48-Mesenchymal population. Since
phosphorylation of β-catenin marks it for degradation, this suggests
that the 48-Mesenchymal population harbors increased β-catenin levels
and activity.
To verify that the spontaneous EMT identified in 48RHMECs was a
general consequence of HMEC transformation and not a patient-specific
artifact, HMECs isolated from a second patient that had undergone a
reduction mammoplasty were subjected to the genetically defined, step-
wise transformation protocol. HMECs from SJ were virally transduced
with the same transforming genetic events. Like the transformed 48R
HMECs, a population of cells with a spindle-shaped morphology
indicative of mesenchymal cells emerged within the transformed SJ-
shp16-shp53–M/R epithelial cells. The cells with mesenchymal-like
morphology (SJ-Mesenchymal) were separated from the epithelial cells
(SJ-Epithelial) by differential trypsinization (Figure 2A). Flow cytometry
determined that the SJ-Epithelial population was 91.7% positive for the
epithelial marker EpCAM, while only 2.3% of the SJ-Mesenchymal
population expressed EpCAM (Figure 2B). Western blot and confocal
analyses again confirmed that the epithelial marker E-cadherin is
expressed exclusively in the SJ-Epithelial cells, while the mesenchymal
marker vimentin is expressed in the SJ-Mesenchymal cells (Figure 2, C
and D). These data suggest that inhibiting the tumor suppressors p16
and p53 while expressing the oncogenes MYC and RAS efficiently
drives AIG. During this genetically defined, stepwise transformation
protocol, a population of cells with mesenchymal-like morphology that
can be separated from the epithelial cell population emerges.
Figure 2. Spontaneous EMT is a common consequence of HMEC transformation. SJ HMECs were transformed as in Figure 1. (A) Bright-
fieldmicroscopy (×4) of epithelial (SJ-Epithelial) andmesenchymal-like (SJ-Mesenchymal) populations separated by differential trypsinization.
The SJ-Epithelial and SJ-Mesenchymal cells were analyzed by (B) flow cytometry for EpCAM, (C) Western blot analysis, or (D) confocal
microscopy (×100) for E-cadherin (red), vimentin (green), and nuclei (blue).
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Mesenchymal-Like Cells Have Properties Associated with
Breast CSCs
Previous reports have demonstrated that EMT generates cells
with properties associated with CSC phenotypes including a
CD24−/CD44+ surface marker profile [14]. Thus, we hypothe-
sized that the spontaneous EMT that occurred during HMEC
transformation would generate breast CSCs. To test this hypothesis,
48-Mixed, 48-Epithelial, and 48-Mesenchymal cells were character-
ized for CD24 and CD44 cell surface marker expression. Flow cy-
tometry revealed that the 48-Epithelial cells consisted primarily of a
CD24+/CD44− population indicative of a non-CSC population (epi-
thelial/non-CSC), while the separated 48-Mesenchymal cells consisted
primarily of a CD24−/CD44+ population indicative of a CSC popula-
tion (mesenchymal/CSC) (Figure 3A). Similar results were obtained
using the SJ-Epithelial and SJ-Mesenchymal cells (Figure 3B).
A property associated with CSCs is their ability to generate
tumors with few cells. To determine if the 48-Mesenchymal and
SJ-Mesenchymal cells acquired characteristics of CSCs compared to
the 48-Epithelial and SJ-Epithelial cells, each cell type was plated in
Figure 3. Mesenchymal-like cells acquire properties of CSCs. (A)
48-Mixed, 48-Epithelial, and 48-Mesenchymal cells and (B) SJ-
Epithelial and SJ-Mesenchymal cells were analyzed by flow cyto-
metry for CD24 and CD44 expression. AIG of (C) 48-Mesenchymal
and 48-Epithelial cells and (D) SJ-Mesenchymal and SJ-Epithelial
cells was assessed at diminishing cell numbers. (E) Flow cytometry
of 48-Epithelial and 48-Mesenchymal cells before (Pre-agar) and
after (Recovered) AIG.
Figure 4.Mesenchymal-like cells form tumors in vivo. Representative
hematoxylin and eosin staining (×400) of (A) a primary tumor and
(B) a liver tumor formed by 48-Mesenchymal cells. (C) Flow cytometry
of cells cultured from a primary tumor xenograft.
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soft agar at diminishing cell number to assess AIG. At low plating
densities, the 48-Mesenchymal and SJ-Mesenchymal cells formed
nearly 10 times more colonies than their epithelial counterparts (Fig-
ure 3, C and D). To verify that AIG is associated with a CSC profile,
we recovered soft agar colonies generated by 48-Mesenchymal and
48-Epithelial populations and demonstrated that recovered cells
had a CD24−/CD44+ CSC surface marker profile, regardless of the
starting profile of the cells (Figure 3E ). These results suggest that
AIG is associated with a CD24−/CD44+ CSC profile.
Since the 48-Mesenchymal cells grew well in agar at limiting dilu-
tions and demonstrated a breast CSC profile, we hypothesized that
these cells would generate tumors in immune-compromised mice.
48-Epithelial or 48-Mesenchymal populations were injected into
athymic nude mice, and tumors were resected at 12 weeks. The
48-Epithelial cells did not form any tumors in vivo, while five tumors
were formed from six injections of the 48-Mesenchymal cells, con-
sistent with their ability for AIG and their CD24−/CD44+ CSC surface
marker profile. 48-Mesenchymal xenograft tumors were high-grade
carcinoma with extensive necrosis, a large degree of nuclear pleo-
morphism, and numerous atypical mitotic figures, consistent with
poorly differentiated breast cancer (Figure 4A). One macroscopic liver
tumor was generated by the 48-Mesenchymal cells. The liver tumor
was also poorly differentiated similar to the primary flank tumors
(Figure 4B). One primary tumor was dissociated for tissue culture
growth. Analysis of the cultured cells revealed a CD24−/CD44+ CSC
profile (Figure 4C ). These data demonstrate that only the transformed
cells with a CD24−/CD44+ CSC profile were capable of forming
tumors in mice consistent with their ability for AIG in limiting
dilutions. Interestingly, the tumors formed were poorly differen-
tiated and maintained a CD24−/CD44+ CSC profile, suggesting that
these cells were incapable of differentiation, inconsistent with a stem
cell phenotype.
Autocrine and Paracrine Cytokine Signaling Generate
Mesenchymal/CSC through EMT
TGF-β signaling induces EMT in HMEC transformation models
[23,24]. Consistent with these observations, the targeted EMT qRT-
PCR array analysis demonstrated that TGF-β1 and TGF-β3 were
elevated in the 48-Mesenchymal cells (Figure 1F ). Therefore, we
hypothesized that TGF-β signaling played a significant role in the
spontaneous EMT observed during HMEC transformation. A targeted
TGF-β superfamily signaling pathway qRT-PCR array was used to
identify differences in TGF-β superfamily gene expression between
48-Epithelial and 48-Mesenchymal cells. Of 84 TGF-β superfamily
target genes on the array, 34 (40%) were differentially expressed more
than two-fold between the 48-Epithelial and 48-Mesenchymal cells.
This analysis confirmed the induction of TGF-β1 and TGF-β3 gene
expression in the 48-Mesenchymal cells, as well as increased gene
expression of the type I and type III TGF-β receptors (Figure 5A). A
number of the related bone morphogenetic protein ligand genes includ-
ing BMP2, BMP4, BMP5, and growth differentiation factor 5 (GDF5),
as well as the bone morphogenetic protein receptor, type IB (BMPR1B)
receptor (Figure 5A), were also increased in the 48-Mesenchymal cells.
The expression of the activin ligand inhibitors INHA and INHBA were
decreased in the 48-Mesenchymal cells compared to their 48-Epithelial
counterparts (Figure 5A). These data suggest that the spontaneously
Figure 5. TGF-β drives EMT and acquisition of CSC properties. (A) Gene expression differences of 48-Mesenchymal compared to
48-Epithelial cells. 48-Epithelial cells exposed to exogenous TGF-βwere analyzed by (B) Western blot, (C) flow cytometry, or (D) for AIG
with 48-Mesenchymal cells (48-Mes) as a positive control. At the time of plating, TGF-β was removed from 48-Epithelial cells that
were previously exposed (TGF-β Removed).
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generated 48-Mesenchymal population is derived from an EMT driven
at least partially by enhanced autocrine TGF-β signaling.
Tumor epithelial cells respond to aberrantly elevated cytokines,
chemokines, and growth factors in the tumor microenvironment,
which can be produced by the cancer cells themselves or a variety
of tumor-associated stromal cells. We hypothesized that elevated
TGF-β from the tumor microenvironment would also induce
EMT in transformed HMECs generating a mesenchymal/CSC pop-
ulation. 48-Epithelial cells were treated with recombinant TGF-β1 to
recapitulate elevated cytokine levels in the tumor microenvironment.
TGF-β1 exposure increased vimentin protein, decreased E-cadherin
protein, and induced the acquisition of a CD24−/CD44+ CSC pro-
file (Figure 5, B and C ). 48-Epithelial cells treated for 2 weeks with
TGF-β1 were plated in soft agar for 2 weeks with or without sus-
tained TGF-β1 treatment, and AIG was assessed. Consistent with
the CD24−/CD44+ CSC profile of the 48-Epithelial cells treated
continuously with TGF-β1, these cells grew efficiently in agar sim-
ilar to positive control (48-Mesenchymal; Figure 5D). Interestingly,
removal of TGF-β1 at the time of plating resulted in inefficient
agar growth similar to negative controls (48-Epithelial; Figure 5D).
TGF-β ligand binds to TGFβRII and TGFβRI resulting in phos-
phorylation of TGFβRI. Phosphorylated TGFβRI induces phosphor-
ylation of the receptor-associated SMAD2 or SMAD3 proteins,
which can then complex with SMAD4 and translocate to the nucleus
to affect gene expression. SMAD2/4 or SMAD3/4 complexes are
inhibited by SMAD7. Alternatively, TGF-β can also activate TAK-1
[25–27]. We sought to determine whether exogenous TGF-β–induced
EMT and generation of CSC required the TGF-β receptor complex,
SMAD proteins, and/or TAK-1. 48-Epithelial cells were infected with
retroviruses encoding DN-TGFβRII, DN–TAK-1, SMAD7, or vector
control retroviruses. Analysis of CD24 and CD44 demonstrated
that all 48-Epithelial derivatives retained a CD24+/CD44− non-
CSC surface marker profile and did not form colonies when tested
for AIG, similar to the parental 48-Epithelial population (Figure 6A).
Treatment with TGF-β1 induced a CD24−/CD44+ CSC population
and AIG in the vector control and DN–TAK-1 derivatives, indicating
that TAK-1 signaling was not required for the acquisition of CSC prop-
erties (Figure 6, A and B). In contrast, expression of DN-TGFβRII
or SMAD7 efficiently suppressed the emergence of a CD24−/CD44+
population and AIG in response to TGF-β1 treatment (Figure 6, A and
B). Taken together, these results suggest that TGF-β1 engages SMAD-
mediated signaling to induce EMT and generate a mesenchymal/
CSC population capable of AIG. Interestingly, these data also suggest
that continuous TGF-β1 signaling is required for maintenance of
mesenchymal/CSC populations.
Paracrine Cytokine Signaling Elicits
Epithelial-Mesenchymal Plasticity
Previous studies have determined that TGF-β–induced EMT of
murine mammary epithelial cells requires activation of the PI3K-
AKT-mTOR signaling pathway [28,29]. Indeed, the 48-Mesenchymal/
CSC population that arose through spontaneous EMT harbored in-
creased AKT protein phosphorylated at serine 473 indicative of mTOR
activation. This suggests a potential therapeutic opportunity to target
CSC within tumors by inhibiting TGF-β or PI3K-AKT-mTOR ac-
tivation. Thus, we hypothesized that chemical inhibitors of the TGF-β
and PI3K-AKT-mTOR signaling pathways would inhibit generation
of CSC and AIG in response to exogenous cytokine exposure. The
48-Epithelial cells were treated for 2 weeks with TGF-β1 alone or in
combination with the PI3K inhibitor LY, the mTOR inhibitor RAP,
or the TGF-βRI inhibitor SB. As expected, treatment of 48-Epithelial cells
with TGF-β1 for 2 weeks increased the CD24−/CD44+ CSC popula-
tion from 5.9% to 28.7% (Figure 7A). Co-administration of TGF-β1
with LY or RAP led to 19.5% and 30.0% CD24−/CD44+ CSC, re-
spectively, similar to TGF-β1 treatment alone (Figure 7A). However,
co-administration of SB completely abrogated the ability of TGF-β1 to
generate CD24−/CD44+ CSC populations (Figure 7A). This result sug-
gests that specific inhibition of the TGF-β pathway, not PI3K-AKT-
mTOR signaling, is capable of blocking EMT and CSC generation
induced by microenvironmental TGF-β1.
Since our results suggested that continuous TGF-β exposure was
required to sustain AIG, we hypothesized that mesenchymal/CSC
generated by TGF-β conversion may also be reverted to epithelial/
non-CSC by inhibiting the TGF-β signaling pathway. 48-Epithelial
cells were treated for 3 weeks with TGF-β1 to generate mesenchymal/
CSC. At 3 weeks, the treated cells were separated into the following
three groups: 1) continued TGF-β1 treatment alone, 2) removal of
TGF-β1, or 3) continued TGF-β1 treatment with co-administration
of LY, RAP, or SB chemical inhibitors for 3 weeks. 48-Epithelial cells
treated continuously with TGF-β1 for 6 weeks were 88.9% CD24−/
CD44+ CSC (Figure 7B). Cells that were exposed for 3 weeks to
TGF-β1 and then had it removed for 3 weeks were 33.5% CD24−/
CD44+ CSC, with strongly suppressed AIG (Figure 7B). Cells treated
with TGF-β1 for 3 weeks and then TGF-β1 together with LY, RAP,
or SB for three additional weeks were 87.2%, 87.5%, and 43.2%
CD24−/CD44+ CSC, respectively (Figure 7B). As described above,
Figure 6. TGF-β–induced CSCs require receptor/SMAD signaling.
48-Epithelial cells expressing DN-TGFβRII, SMAD7, DN–TAK-1, or
control cells (Vector) were analyzed by (A) flow cytometry with
percent CD44+ in the lower right corners or for (B) AIG before and
after exposure to exogenous TGF-β.
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LY or RAP was unable to suppress AIG, consistent with the inability
of each of the inhibitors to decrease the CD24−/CD44+ CSC
(Figure 7C ). Treatment with SB suppressed both the CD24−/CD44+
CSC population and AIG, similar to the cells that had TGF-β1
removed (Figure 7, B and C). These data suggest that mesenchymal/
CSC populations induced by TGF-β in the tumor microenvironment
may be reverted to epithelial/non-CSC by inhibiting TGF-β signaling
within these cells. Interestingly, the 48-Mesenchymal cells generated
spontaneously during transformation by autocrine TGF-β signaling
did not respond to type I receptor inhibition by SB (Figure 7,D and E).
Discussion
Metastasis is the overwhelming cause of breast cancer patient mortality,
yet our understanding of this complex problem remains limited. An
emerging concept for metastasis is that cellular plasticity associated
with EMT and subsequent mesenchymal-to-epithelial transition is
critical for the ability of cancer cells to disseminate from the primary
tumor site, survive circulation, and establish a growing tumor at a
secondary site. Indeed, a population of pancreatic cells that exhibit
EMT and stem cell properties was locally invasive and led to the
presence of CTCs in the bloodstream even before frank malignancy
could be observed [30]. Importantly, when the pancreatic cancer
cells were separated on the basis of their epithelial or mesenchymal
markers, each population produced similar mixed tumors and metas-
tases. This study illustrates the importance of epithelial-mesenchymal
plasticity as a tumor- and metastasis-promoting property. A recent
study further supports a role for EMT in metastasis by demonstrating
that breast CTCs are highly enriched for mesenchymal markers, and
increases in circulating mesenchymal cells are associated with disease
progression [31]. In contrast, breast cancer patient metastases typically
reflect the primary tumor histologically, suggesting that circulating
mesenchymal cellsmust revert to an epithelial state to promotemetastatic
outgrowth [32–34]. We report here a model of epithelial-mesenchymal
plasticity that is generated by cooperation between intrinsic genetic
changes within a developing cancer cell and exogenous, tumor micro-
environmental cytokine signaling.
Previously, we described a genetically defined, stepwise model of
HMEC transformation and identified TGF-β signaling as a key reg-
ulator of RAS-mediated senescence in cells lacking p16 and p53 [18].
Once the cytostatic effects of TGF-β were dismantled by constitutive
c-MYC expression, RAS-mediated transformation proceeded unchecked.
Importantly, while constitutive c-MYC expression suppressed TGF-β–
mediated senescence, it allowed the transformed HMECs to retain the
TGF-β receptors and SMAD proteins responsible for inducing EMT,
which we describe here. During stepwise transformation of HMECs, a
subpopulation of mesenchymal-like cells was generated by spontaneous
EMT (Figure 8A). The mesenchymal-like cells acquired properties
associated with breast CSCs. Increased gene expression of several com-
ponents of TGF-β, BMP, and WNT signaling was identified in the
spontaneous mesenchymal/CSC population, suggesting that autocrine
TGF-β signaling was at least partly responsible for the spontaneous
EMT. The spontaneous mesenchymal/CSC did not respond to
pharmacologic inhibition of TGF-β signaling and formed poorly differ-
entiated tumors in immune-compromised mice, indicating that they
are locked in a state associated with EMT and breast CSCs but are
incapable of differentiating. Thus, spontaneous EMT does not demon-
strate the epithelial-mesenchymal plasticity posited to be required for
breast cancer metastasis.
Studies of the tumor interstitial fluid have identified more than
1000 proteins that have been secreted, externalized due to cell death,
or shed by membrane vesicles into the breast tumor microenviron-
ment [35]. Many of these proteins are secreted from the 20 or more
different cell types that are present within the tumor stroma [36].
Cytokines top the list of tumor-associated secreted factors and are
likely to have important effects on epithelial-mesenchymal plasticity.
Our study alone has identified the potential involvement of
WNT5A, GDF5, BMP2, BMP4, BMP5, TGF-β1, and TGF-β3 as
potential regulators of EMT in our model. To explore the possibility
that cytokines present in the tumor microenvironment influence
epithelial-mesenchymal plasticity, transformed epithelial cells were
exposed to TGF-β. Exposure to exogenous TGF-β increased AIG,
induced EMT, and generated mesenchymal/CSC. Interestingly,
removal of the exogenous TGF-β caused reversion of the mesenchymal/
Figure 7. Epithelial-mesenchymal plasticity is induced by exoge-
nous cytokine signaling. (A) 48-Epithelial cells exposed to TGF-β
alone or in combination with inhibitors to PI3K (LY), mTOR (RAP), or
TGFβRI (SB) were analyzed by flow cytometry. 48-Epithelial cells
treated with TGF-β for 6 weeks (continuous), for 3 weeks, and then
removed for 3 weeks (removed) or for 3 weeks and then in com-
bination with LY, RAP, or SB for 3 weeks were analyzed by (B) flow
cytometry with percent CD44+ in the lower right corners and for
(C) AIG. Spontaneous 48-Mesenchymal cells (48-Mes) were treated
for 2weekswith SB and analyzed by (D) flow cytometry or for (E) AIG.
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CSC to epithelial/non-CSC, indicating that the CSCs become addicted
to this key microenvironmental cue. Thus, epithelial-mesenchymal
plasticity was generated by exposure and removal of exogenous TGF-β
(Figure 8B). It is yet to be determined whether the myriad of other
tumor-associated cytokines influences epithelial-mesenchymal plastic-
ity. Ourmodel can be used to define how signaling interactions between
extrinsic and intrinsic factors influence epithelial tumor plasticity.
Our ultimate goal is to identify novel therapeutic strategies that
inhibit the ability of tumor microenvironmental factors to induce
epithelial-mesenchymal plasticity with hopes of diminishing a tumor’s
capacity to undergo metastasis. TGF-β signaling has been proposed as a
therapeutic target, and TGF-β inhibitors are currently being developed
for clinical use [37–39]. Indeed, disruption of canonical TGF-β receptor/
SMAD signaling within fully transformed HMECs abrogated the abil-
ity of exogenous TGF-β to induce AIG and generate mesenchymal/
CSC populations. Moreover, pharmacologic inhibition of TGF-β sig-
naling in our plasticity model also decreased AIG and mesenchymal/
CSC populations. This suggests that targeting TGF-β signaling, and
potentially additional tumor-associated cytokine signaling, may be an
effective strategy to inhibit generation of mesenchymal/CSC. Suppres-
sing TGF-β signaling remains risky, as it is clearly involved in organis-
mal homeostasis and is a crucial tumor suppressor early in cancer
development. Therefore, we propose to use our model of epithelial-
mesenchymal plasticity to identify novel tumor-associated cytokines
that drive EMT and the acquisition ofCSCproperties. Identifying novel
tumor-associated cytokines that regulate epithelial-mesenchymal
plasticity and CSC properties is highly desirable, given their potential
impact on metastatic outgrowth. By inhibiting the signaling pathways
in tumor cells activated by exogenous cytokines from the tumor micro-
environment, we may be able to block the generation of mesenchymal/
CSC and subsequent tumor cell spread.
Our study demonstrates that exogenous cytokines present in the
tumor microenvironment can cooperate with intrinsic genetic changes
to produce epithelial-mesenchymal plasticity. If the key signals that reg-
ulate tumor cell plasticity originate from the tumor-associated stromal
cells of the primary tumor, then CTCs that have traveled to secondary
sites will encounter a significant shift in microenvironmental cues. As
CTCs arrive at secondary sites where the original cytokine signal is no
Figure 8. HMEC transformation generates spontaneous EMT and plastic cell populations. (A) Representation of the stepwise, genetically
defined transformation protocol producing stable spontaneous EMT cells. Markers and properties of the isolated populations are listed.
(B) Representation of the epithelial-mesenchymal plasticity identified in transformed epithelial populations by exogenous cytokine expo-
sure. (C) Representation of the proposed role of epithelial-mesenchymal plasticity in metastasis induced by the tumor microenvironment.
1108 The Tumor Microenvironment Elicits Cell Plasticity Junk et al. Neoplasia Vol. 15, No. 9, 2013
longer present, only the cells that are capable of epithelial-mesenchymal
plasticity will generate metastatic outgrowth (Figure 8C). As such, the
cross talk between tumor epithelial and tumor-associated stromal cells
may be an effective target for therapy to reduce metastasis. This may be
accomplished by targeting the tumor epithelial cells themselves as
described here or targeting the tumor-associated stromal cells that are
producing the cytokine signals.
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